Subcutaneous RYBREVANT (amivantamab) demonstrates 77% ORR in 1L treatment of patients with certain types of advanced head and neck cancer November 4, 2026
Novocure enters clinical trial collaboration and supply agreement with Verastem Oncology to evaluate TTFields therapy, chemo and VS-7375 to treat pancreatic cancer November 4, 2026
Updated data announced from Cohort 4 of Ph 1/2 GOBLET study of pelareorep + Tecentriq in 2L+ SCAC patients November 4, 2026
Dren Bio Announces $350 Million Financing to Advance Dibotatug Toward Commercialization and Accelerate Development of Broader Pipeline November 4, 2026
Ph 3 LiGeR-HN1 trial of Petosemtamab + pembrolizumab versus pembrolizumab alone met both primary endpoints in PD-L1 positive HNSCC patients November 4, 2026
Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044 November 4, 2026
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD Combo with Novel CAR-T for Multiple Myeloma November 4, 2026
Ph 3 IMpactMF trial of imetelstat in JAK inhibitor R/R myelofibrosis to be discontinued based on DMC recommendation November 4, 2026
Positive Results from Ph 2 BELLA Trial of Lifyorli, Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer Reported November 4, 2026
Statistically Significant OS/ORR Improvements reported with Petosemtamab Combo at First Interim Analysis in 1L R/M Patients with PD-L1+ Head and Neck Cancer November 4, 2026
Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer November 4, 2026
ELREXFIO demonstrated clinically meaningful & statistically significant PFS benefit for RRMM patients in Ph 3 MagnetisMM-32 trial November 4, 2026
Updated results from Cohorts 1 and 2 of Ph 2 IOV-LUN-202 trial in previously treated non-squamous mNSCLC announced November 4, 2026
Additional Positive Results of Combi-TED Ph 2 Trial with Tedopi® (OSE2101) in metastatic NSCLC Announced November 4, 2026
Results from UNICORN Ph 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer Published in Nature Medicine November 4, 2026
FDA approves the investigator-sponsored clinical trial (IST) of HMBD-002 in combination with venetoclax and azacitidine in AML and MDS November 4, 2026
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer November 4, 2026
